Opportunity radar
4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05
Showing50 of 30,058
Pharma (A61K)Therapy methods (A61P)Med devices (A61M)Agriculture (A01)Hand tools (B25)Consumer (A47)Energy (H01M)AI / ML (G06N)
| Patent # | Title | Assets | Issued | Expires | Fwd cites | Score |
|---|---|---|---|---|---|---|
| 12605332 | Transdermal delivery formulations | 🖼🧊📄§ | 2026-04-21 | 2042-10-31 | 0 | 31 |
| 12606796 | Delivery of oncolytic viruses using dendritic cells | 🖼🧊📄§ | 2026-04-21 | 2040-05-07 | 0 | 31 |
| 12605412 | Microbial compositions for improving the efficacy of anticancer treatments based on immune checkpoint inhibitors and/or tyrosine kinase inhibitors and markers of responsiveness to such treatments | 🖼🧊📄§ | 2026-04-21 | 2040-09-29 | 0 | 31 |
| 12605355 | HA-paclitaxel conjugate for treatment of mesothelioma | 🖼🧊📄§ | 2026-04-21 | 2041-04-07 | 0 | 31 |
| 12606538 | Benzo[b]selenophene sting regulator, preparation method and use thereof | 🖼🧊📄§ | 2026-04-21 | 2042-04-18 | 0 | 31 |
| 12606540 | Triazolone compound | 🖼🧊📄§ | 2026-04-21 | 2041-05-24 | 0 | 31 |
| 12606529 | Sulfur and amide tropolone inhibitors of nucleotidyl transferases and uses therefor | 🖼🧊📄§ | 2026-04-21 | 2040-05-03 | 0 | 31 |
| 12605396 | Methods of treating mastitis with an orthosomycin antimicrobial compound | 🖼🧊📄§ | 2026-04-21 | 2041-12-23 | 0 | 31 |
| 12605368 | Suppression of neuroinflammation and composition and method therefor | 🖼🧊📄§ | 2026-04-21 | 2041-03-31 | 0 | 31 |
| 12605369 | Amido-substituted heterocyclic compounds and methods of use thereof for the treatment of herpes viruses | 🖼🧊📄§ | 2026-04-21 | 2040-12-16 | 0 | 31 |
| 12605371 | Combination therapy for cancer | 🖼🧊📄§ | 2026-04-21 | 2041-07-26 | 0 | 31 |
| 12605372 | Combination therapy for the treatment of cancer | 🖼🧊📄§ | 2026-04-21 | 2042-11-09 | 0 | 31 |
| 12605382 | Pharmaceutical composition for preventing, alleviating, or treating cancer containing 2,6-dichloro-4-(4-(4-hydroxycyclohexylamino)-7H- pyrrolo[2,3-d]pyrimidin-5-yl)phenol as active ingredient | 🖼🧊📄§ | 2026-04-21 | 2042-05-03 | 0 | 31 |
| 12605387 | Treatment of cancers using PI3 kinase isoform modulators | 🖼🧊📄§ | 2026-04-21 | 2040-07-24 | 0 | 31 |
| 12605434 | Composition for preventing or treating autoimmune diseases | 🖼🧊📄§ | 2026-04-21 | 2042-09-13 | 0 | 31 |
| 12606558 | Condensed pyrazole derivatives as inhibitors of SARM1 | 🖼🧊📄§ | 2026-04-21 | 2041-04-07 | 0 | 31 |
| 12606566 | Substituted cyclopenta[4,5]pyrrolo[1,2-a]pyrazines as bruton's tyrosine kinase inhibitors | 🖼🧊📄§ | 2026-04-21 | 2041-06-18 | 0 | 31 |
| 12606594 | Heterotandem bicyclic peptide complexes | 🖼🧊📄§ | 2026-04-21 | 2042-02-02 | 0 | 31 |
| 12606610 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | 🖼🧊📄§ | 2026-04-21 | 2043-08-16 | 0 | 31 |
| 12606607 | T cell receptors | 🖼🧊📄§ | 2026-04-21 | 2042-10-13 | 0 | 31 |
| 12606609 | Polypeptides having improved properties | 🖼🧊📄§ | 2026-04-21 | 2041-01-26 | 0 | 31 |
| 12606606 | Nucleic acid construct that encodes chimeric rhodopsin | 🖼🧊📄§ | 2026-04-21 | 2040-09-11 | 0 | 31 |
| 12606617 | Composition comprising an IgE antibody | 🖼🧊📄§ | 2026-04-21 | 2041-04-23 | 0 | 31 |
| 12606613 | Humanized anti-C5a antibodies | 🖼🧊📄§ | 2026-04-21 | 2041-05-06 | 0 | 31 |
| 12606616 | PLK1 inhibitor in combination with anti-angiogenics for treating metastatic cancer | 🖼🧊📄§ | 2026-04-21 | 2045-12-08 | 0 | 31 |
| 12606625 | Antibody binding specifically to B7—H3 and use thereof | 🖼🧊📄§ | 2026-04-21 | 2040-07-08 | 0 | 31 |
| 12606633 | Methods and compositions for anti-CD73 antibodies and variants | 🖼🧊📄§ | 2026-04-21 | 2042-01-25 | 0 | 31 |
| 12606634 | Antibody-pyrrolobenzodiazepine derivative conjugate which binds caludin-6 and claudin-9 | 🖼🧊📄§ | 2026-04-21 | 2044-04-08 | 0 | 31 |
| 12606805 | Tymovirus virus and virus-like particles as nanocarriers for imaging and therapeutic agents | 🖼🧊📄§ | 2026-04-21 | 2043-08-29 | 0 | 31 |
| 12606825 | Compositions and methods for modulating RPGR expression | 🖼🧊📄§ | 2026-04-21 | 2041-03-04 | 0 | 31 |
| 12606571 | Macrocyclic compounds and uses thereof | 🖼🧊📄§ | 2026-04-21 | 2044-04-09 | 0 | 31 |
| 12606552 | Bifunctional compound, preparation method therefor, and use thereof | 🖼🧊📄§ | 2026-04-21 | 2042-09-09 | 0 | 31 |
| 12606827 | Compounds for treatment of osteoarthritis | 🖼🧊📄§ | 2026-04-21 | 2043-05-19 | 0 | 31 |
| 12606619 | Human monoclonal antibodies against TIGIT for immune related diseases | 🖼🧊📄§ | 2026-04-21 | 2041-06-23 | 0 | 31 |
| 12606620 | Anti-LILRB1 antibody and uses thereof | 🖼🧊📄§ | 2026-04-21 | 2041-07-27 | 0 | 31 |
| 12606639 | Antigen binding proteins | 🖼🧊📄§ | 2026-04-21 | 2045-05-20 | 0 | 31 |
| 12605485 | Nanoparticles to promote wound healing and antimicrobial infection control | 🖼🧊📄§ | 2026-04-21 | 2042-10-26 | 0 | 31 |
| 12605472 | Radiolabeling of anti-CD45 immunoglobulin and methods of use thereof | 🖼🧊📄§ | 2026-04-21 | 2040-09-17 | 0 | 31 |
| 12605463 | Tolerogenic artificial antigen-presenting cells | 🖼🧊📄§ | 2026-04-21 | 2040-06-12 | 0 | 31 |
| 12605455 | CAR peptide for improved coronavirus survival | 🖼🧊📄§ | 2026-04-21 | 2041-03-19 | 0 | 31 |
| 12605456 | Composition and method for HIP1-targeting inhibitor compounds | 🖼🧊📄§ | 2026-04-21 | 2042-05-28 | 0 | 31 |
| 12605442 | Production of vaccines comprising inactivated SARS-CoV-2 viral particles | 🖼🧊📄§ | 2026-04-21 | 2041-03-05 | 0 | 31 |
| 12605439 | Universal influenza vaccine compositions | 🖼🧊📄§ | 2026-04-21 | 2041-12-28 | 0 | 31 |
| 12605437 | Single shot Chikungunya virus vaccine | 🖼🧊📄§ | 2026-04-21 | 2040-08-10 | 0 | 31 |
| 12605429 | Proteins having pneumococcal capsule degrading activity and methods of use | 🖼🧊📄§ | 2026-04-21 | 2043-05-19 | 0 | 31 |
| 12605457 | Modified EGFR antibody with reduced affinity, drug conjugate, and use thereof | 🖼🧊📄§ | 2026-04-21 | 2041-11-19 | 0 | 31 |
| 12605433 | Antibody specifically binding to PTK7 and use thereof | 🖼🧊📄§ | 2026-04-21 | 2041-07-16 | 0 | 31 |
| 12605353 | PDIA4 inhibitors and use thereof for inhibiting β-cell pathogenesis and treating diabetes | 🖼🧊📄§ | 2026-04-21 | 2040-11-15 | 0 | 31 |
| 12605354 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions | 🖼🧊📄§ | 2026-04-21 | 2041-02-19 | 0 | 31 |
| 12605356 | Methods of treating pancreatic cancer | 🖼🧊📄§ | 2026-04-21 | 2043-10-26 | 0 | 31 |